14.51

3.97% -0.60

Enanta Pharmaceuticals Inc (ENTA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$15.11

Offen:

$14.9

24-Stunden-Volumen:

204.96K

Relative Volume:

1.05

Marktkapitalisierung:

$421.93M

Einnahmen:

$69.21M

Nettoeinkommen (Verlust:

$-61.98M

KGV:

-5.5922

EPS:

-2.5947

Netto-Cashflow:

$-9.61M

1W Leistung:

+0.00%

1M Leistung:

+28.63%

6M Leistung:

+6.85%

1J Leistung:

+83.90%

1-Tages-Spanne:

$14.41

$15.10

1-Wochen-Bereich:

$14.26

$15.51

52-Wochen-Spanne:

$6.435

$17.15

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Firmenname

Enanta Pharmaceuticals Inc

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

617 607 0800

Adresse

4 KINGSBURY AVENUE, WATERTOWN, MA

Mitarbeiter

120

Twitter

@EnantaPharma

Nächster Verdiensttermin

2026-08-10

Neueste SEC-Einreichungen

ENTA's Discussions on Twitter

Compare ENTA vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ENTA Enanta Pharmaceuticals Inc	14.51	423.96M	69.21M	-61.98M	-9.61M	-2.5947
VRTX Vertex Pharmaceuticals Inc	529.59	126.07B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.81	65.37B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	916.80	57.70B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	313.04	40.19B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.99	39.82B	742.00K	-1.37B	-1.07B	-7.0731

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-26	Eingeleitet	Rodman & Renshaw	Buy
2025-11-14	Eingeleitet	JP Morgan	Overweight
2025-10-01	Hochstufung	Jefferies	Hold → Buy
2025-07-28	Fortgesetzt	H.C. Wainwright	Buy
2023-08-09	Herabstufung	JP Morgan	Neutral → Underweight
2023-08-08	Herabstufung	Jefferies	Buy → Hold
2022-12-09	Eingeleitet	H.C. Wainwright	Buy
2022-07-06	Hochstufung	Evercore ISI	In-line → Outperform
2022-06-01	Hochstufung	Evercore ISI	Underperform → In-line
2021-10-07	Eingeleitet	Jefferies	Buy
2021-09-09	Eingeleitet	SVB Leerink	Mkt Perform
2021-01-29	Hochstufung	JP Morgan	Underweight → Neutral
2020-11-24	Eingeleitet	Evercore ISI	Underperform
2020-08-28	Fortgesetzt	ROTH Capital	Buy
2020-08-26	Eingeleitet	Piper Sandler	Overweight
2020-07-27	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2020-03-17	Hochstufung	Robert W. Baird	Neutral → Outperform
2019-11-22	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2019-09-26	Herabstufung	JP Morgan	Neutral → Underweight
2019-05-24	Eingeleitet	Wolfe Research	Outperform
2019-04-23	Hochstufung	Berenberg	Hold → Buy
2018-12-13	Eingeleitet	Berenberg	Hold
2018-06-06	Eingeleitet	ROTH Capital	Buy
2018-02-08	Herabstufung	JP Morgan	Overweight → Neutral
2018-01-02	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2017-11-21	Bestätigt	RBC Capital Mkts	Outperform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2017-07-11	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2016-04-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Bestätigt	Barclays	Underweight
2015-10-23	Herabstufung	Barclays	Equal Weight → Underweight
2015-10-23	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform

Alle ansehen

Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten

Jul 02, 2026

Federal Circuit Rules Written Description Standard Governs Patent Priority In Enanta Pharmaceuticals v. Pfizer (PFE) - londoninsider.co.uk

Jul 02, 2026

Jul 01, 2026

Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView

Jul 01, 2026

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Enanta Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Vance Terry - Moomoo

Jun 28, 2026

Enanta Pharmaceuticals | SCHEDULE 13G/A: Others - Moomoo

Jun 28, 2026

Jun 27, 2026

AbbVie, Enanta announce EU label expansion for hepatitis C therapy, Maviret - MSN

Jun 27, 2026

Enanta Pharmaceuticals (ENTA) moves 5.2% higher: Will this strength last? - MSN

Jun 27, 2026

Jun 26, 2026

Enanta Pharmaceuticals sets out pipeline catalysts, shares watched by biotech investors - AD HOC NEWS

Jun 26, 2026

Enanta Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ENTA) - TradingView

Jun 26, 2026

Jun 25, 2026

Pfizer patent win against Enanta over COVID pill upheld by appeals court - MSN

Jun 25, 2026

Price to book forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView

Jun 25, 2026

Price to earnings forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView

Jun 25, 2026

Enterprise value to revenue forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView

Jun 25, 2026

Price to book forward of Enanta Pharmaceuticals, Inc. – TRADEGATE:9EP - TradingView

Jun 25, 2026

ENTA Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

PATENT—Fed. Cir.: Pfizer Inc. prevails in coronavirus-treatment patent dispute with biotechnology company - VitalLaw.com

Jun 24, 2026

Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last? - Yahoo Finance

Jun 24, 2026

EC approves label expansion for Enanta’s Maviret in acute HCV infection - The Pharma Letter

Jun 24, 2026

Form 8K Enanta Pharmaceuticals Inc For: 23 June - Investing.com UK

Jun 24, 2026

Jun 23, 2026

Federal appeals court upholds invalidity of Enanta patent in Pfizer case By Investing.com - Investing.com South Africa

Jun 23, 2026

Form 8K Enanta Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com South Africa

Jun 23, 2026

Federal appeals court upholds invalidity of Enanta patent in Pfizer case - Investing.com UK

Jun 23, 2026

H.C. Wainwright reiterates Enanta stock rating on FDA alignment - Investing.com UK

Jun 23, 2026

Enanta Faces Patent Setback in Paxlovid Litigation - TipRanks

Jun 23, 2026

H.C. Wainwright reiterates Enanta stock rating on FDA alignment By Investing.com - Investing.com South Africa

Jun 23, 2026

[8-K] ENANTA PHARMACEUTICALS INC Reports Material Event - Stock Titan

Jun 23, 2026

CAFC Affirms Enanta Coronavirus Patent Invalid for Lack of Written Description Support in Provisional Application - IPWatchdog.com

Jun 23, 2026

Pfizer Keeps Win in Patent Lawsuit Aimed at Paxlovid Antiviral - Bloomberg Law News

Jun 23, 2026

Enanta (ENTA) Secures EU Approval for Maviret Treatment - GuruFocus

Jun 23, 2026

ENTA Reiterates by HC Wainwright & Co. -- Price Target Maintained at $20 - GuruFocus

Jun 23, 2026

Enanta Pharmaceuticals? Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - marketscreener.com

Jun 23, 2026

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus - BioSpace

Jun 23, 2026

H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo

Jun 23, 2026

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET - Business Wire

Jun 23, 2026

Jun 22, 2026